Dimeric 2-aminoimidazoles are highly active adjuvants for gram-positive selective antibiotics against Acinetobacter...

Area of Science:

• Microbiology
• Medicinal Chemistry
• Infectious Diseases

Background:

• Hospital-acquired infections are rising, with Acinetobacter baumannii as a key contributor.
• Macrolide antibiotics are ineffective against gram-negative bacteria like A. baumannii.
• Previous research identified aryl 2-aminoimidazole (2-AI) adjuvants that potentiate macrolides against A. baumannii.

Purpose of the Study:

• To develop a new class of dimeric 2-AI adjuvants with enhanced activity and reduced toxicity against A. baumannii.
• To identify lead compounds that significantly lower the minimum inhibitory concentrations (MICs) of macrolides against A. baumannii.

Main Methods:

• Synthesis and evaluation of novel dimeric 2-AI compounds.
• Determination of MICs for macrolide-clarithromycin in combination with 2-AI adjuvants against A. baumannii.
• Structure-activity relationship (SAR) studies to optimize adjuvant potency.
• Assessment of mammalian cell toxicity (IC50) against HepG2 cells.

Main Results:

• Dimeric 2-AIs significantly potentiated clarithromycin against A. baumannii, lowering MICs to gram-positive breakpoint levels.
• The parent dimer reduced the clarithromycin MIC from 32 μg/mL to 1 μg/mL.
• Lead dimeric 2-AI compounds achieved even greater reductions in clarithromycin MIC (to 2 μg/mL at 1.5 μM).
• Dimeric 2-AIs demonstrated significantly lower mammalian cell toxicity (IC50 >200 μg/mL) compared to previous aryl 2-AIs, yielding high therapeutic indices (>250).

Conclusions:

• Dimeric 2-AIs represent a promising new class of macrolide adjuvants for treating A. baumannii infections.
• These compounds offer a potential strategy to overcome macrolide ineffectiveness against gram-negative bacteria.
• The reduced toxicity profile suggests a favorable therapeutic window for clinical development.